Origin Bio
Origin is building the largest dataset of how individual cancer cells from real patients respond to drugs and genetic medicines, to license to pharma and AI companies.
Overview
Origin Bio generates patient-derived cancer single-cell datasets by screening the effects of drugs and genetic medicines on tumour cells under the control of what it calls DNA switches, and licenses the resulting data to pharmaceutical and AI drug-discovery companies training models of cancer biology. It is a Winter 2026 YC company with a small team; the dataset and any validation are at an early stage.
Funding
All startupsPages like this
not linked directly; found by shared links- CompanyNotable Labs
Shares Functional (ex vivo) drug testing, Y Combinator and the tag yc.
- CompanyKnown Medicine
Shares Functional (ex vivo) drug testing, Y Combinator and the tag yc.
- CompanyzPREDICTA
Shares Functional (ex vivo) drug testing, Y Combinator and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyLiyfe
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyREPROSENT
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.